Davis Polk advised the joint book-running managers and representatives of the initial purchasers on a Rule 144A offering by Integra LifeSciences Holdings Corporation of $575 million aggregate principal amount of its 0.50% convertible senior notes due 2025 (which included the full exercise of the initial purchasers’ option to purchase additional notes). In addition, Davis Polk advised the counterparties to call spread transactions with Integra LifeSciences Holdings Corporation in connection with the convertible senior notes offering.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery.
The Davis Polk corporate team included partner Yasin Keshvargar and associates Ida Araya-Brumskine and Roman Shapurko. The equity derivatives team included partner Ray Ibrahim and associates Joseph Luizzi and Annie Li. Partner Lucy W. Farr and associate Eitan Ulmer provided tax advice. Counsel Bonnie Chen and associate Yifu Chen provided intellectual property advice. All members of the Davis Polk team are based in the New York office.